TRAW Traws Pharma, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
06:50
Jan 07
Jan 07
January Phase 2 data could rally TRAW before dilution
The author argues Traws Pharma's Ratutrelvir is a next-generation Paxlovid alternative with ritonavir-free once-daily dosing and favorable interim Phase 2 data. The upcoming full Phase 2 readout in January is a catalyst; if the press release is solid, the small-float biotech could rally, but the author plans to exit into any pre-release climb. The main stated risk is that the cash-poor company has used prior run-ups for financing, so any rally may be diluted immediately.
HIGH
About TRAW Investor Commentary
Across the available history and selected sources, Buzzberg tracks TRAW (Traws Pharma, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/RaZE___SoViEt.